Iatrou Christos, Afentakis Nicolaos, Nomikos Tzortzis, Dinas Christos, Stavropoulos-Giokas Catherine, Antonopoulou Smaragdi
Department of Nephrology, General Hospital of Nikaias-Pereaus, Athens, Greece.
Nephron. 2002 May;91(1):86-93. doi: 10.1159/000057609.
Platelet-activating factor (PAF) production during hemodialysis (HD) with cuprophane (CU) membrane has previously been demonstrated, while the results regarding PAF production during HD with AN-69 polyacrylonitrile membrane are dubious. In this study an attempt is made to show that PAF is produced during HD using AN-69 membrane while comparing this production with the corresponding one from HD with CU. Since previous studies have indicated that PAF, like the complement system, could also be implicated in HD-related leukopenia and thrombocytopenia (especially when CU membrane is used), the circulating leukocyte and platelet counts as well as the C3a-desArg and SC5b-9 (soluble, nonlytic form of the terminal complement complex) levels were measured.
Ten hemodialyzed patients were subjected to HD with CU and AN-69 membranes for 2 consecutive weeks (first week with CU and second with AN-69). During the third HD session of each week and at different times (0, 2, 5, 15, 30, 60, 180 and 240 min), the PAF levels in the blood as well as the leukocyte and platelet counts were measured, while the circulating levels of the C3a-desArg and SC5b-9 were measured at 0, 5, 15, 60 and 240 min. PAF was detected by ethanol extraction, followed by purification by column chromatography and high-pressure liquid chromatography and finally quantified by bioassay. The C3a-desArg and SC5b-9 fractions of the complement were measured by immunoassay while an autoanalyzer gave the leukocyte and platelet counts.
Circulating PAF levels were detected at all time intervals during HD with AN-69 (PAF(AN-69)) and CU (PAF(CU)) membranes. At all time intervals PAF(AN-69) < PAF(CU), however, statistically significant differences (s) between the two membranes existed only at 15, 30, 60, 180 and 240 min. The highest PAF(AN-69) and PAF(CU) occurred at 5 and 15 min into dialysis, respectively. The same observations were made for circulating C3a-desArg levels (s existed additionally at 5 min as well). The reduction of the circulating leukocytes had almost a mirror image with the C3a-desArg as well as PAF levels while the maximal reduction of platelets was observed after 2 min into dialysis with both membranes (i.e., simultaneously with the first increase in PAF secretion).
PAF is indeed produced during HD with AN-69 membrane, as it is during HD with CU. At all time intervals during the HD procedure, PAF(AN-69) < PAF(CU). PAF seems to contribute to HD-related leukopenia and thrombocytopenia with both membranes.
先前已证实在使用铜仿膜(CU)进行血液透析(HD)期间会产生血小板活化因子(PAF),而关于使用AN - 69聚丙烯腈膜进行HD期间PAF产生情况的结果尚不确定。在本研究中,试图表明在使用AN - 69膜进行HD期间会产生PAF,并将其产生情况与使用CU膜进行HD时的相应情况进行比较。由于先前的研究表明,PAF与补体系统一样,也可能与HD相关的白细胞减少和血小板减少有关(尤其是在使用CU膜时),因此测量了循环白细胞和血小板计数以及C3a - desArg和SC5b - 9(末端补体复合物的可溶性、非溶解形式)水平。
10例接受血液透析的患者连续2周分别使用CU膜和AN - 69膜进行HD(第一周使用CU膜,第二周使用AN - 69膜)。在每周的第三次HD治疗期间及不同时间点(0、2、5、15、30、60、180和240分钟),测量血液中的PAF水平以及白细胞和血小板计数,同时在0、5、15、60和240分钟测量C3a - desArg和SC5b - 9的循环水平。通过乙醇提取检测PAF,随后通过柱色谱和高压液相色谱进行纯化,最后通过生物测定进行定量。补体的C3a - desArg和SC5b - 9组分通过免疫测定法测量,而自动分析仪给出白细胞和血小板计数。
在使用AN - 69(PAF(AN - 69))和CU(PAF(CU))膜进行HD的所有时间间隔内均检测到循环PAF水平。在所有时间间隔内,PAF(AN - 69) < PAF(CU),然而,两种膜之间的统计学显著差异仅在15、30、60、180和240分钟时存在。PAF(AN - 69)和PAF(CU)的最高值分别出现在透析开始后的5分钟和15分钟。循环C3a - desArg水平也有相同的观察结果(在5分钟时也存在差异)。循环白细胞的减少与C3a - desArg以及PAF水平几乎呈镜像关系,而在使用两种膜进行透析开始2分钟后观察到血小板的最大减少(即与PAF分泌的首次增加同时出现)。
与使用CU膜进行HD时一样,在使用AN - 69膜进行HD期间确实会产生PAF。在HD过程的所有时间间隔内,PAF(AN - 69) < PAF(CU)。PAF似乎在两种膜的情况下都与HD相关的白细胞减少和血小板减少有关。